Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

STEVEN TOLKAN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1871554766
CMS profile
356948
Location
NAPA, CA

General Payments · PY2018–2024

$1,694.73

  • Reported across 41 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$385.98

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $382.90 13
Education $3.08 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $190.03 4
Acerta Pharma LLC $44.25 2
Boehringer Ingelheim Pharmaceuticals, Inc. $42.30 2
Lilly USA, LLC $40.03 2
Retrophin, Inc. $29.86 2
Fresenius USA Marketing, Inc. $21.19 1
Novo Nordisk AS $18.32 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $23.65 1
PY2019 $526.12 7
PY2020 $21.44 1
PY2021 $241.39 7
PY2022 $248.97 4
PY2023 $247.18 7
PY2024 $385.98 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Amgen Inc. $21.09 04/11/2024 Food and Beverage Undisputed 01/23/2026 1116180002 CMS
Amgen Inc. $34.77 10/03/2024 Food and Beverage Undisputed 01/23/2026 1117702180 CMS
Amgen Inc. $9.61 10/15/2024 Food and Beverage Undisputed 01/23/2026 1116180007 CMS
Amgen Inc. $124.56 11/21/2024 Food and Beverage Undisputed 01/23/2026 1116180012 CMS
AstraZeneca Pharmaceuticals LP $21.01 05/07/2024 Food and Beverage Undisputed 01/23/2026 1104245633 CMS
AstraZeneca Pharmaceuticals LP $23.24 12/19/2024 Food and Beverage Undisputed 01/23/2026 1105848728 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.10 01/16/2024 Food and Beverage Undisputed 01/23/2026 1118202440 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.20 11/15/2024 Food and Beverage Undisputed 01/23/2026 1118202444 CMS
Fresenius USA Marketing, Inc. $21.19 02/27/2024 Food and Beverage Undisputed 01/23/2026 1154206248 CMS
Lilly USA, LLC $20.17 04/04/2024 Food and Beverage Undisputed 01/23/2026 1135428816 CMS
Lilly USA, LLC $19.86 10/01/2024 Food and Beverage Undisputed 01/23/2026 1135422153 CMS
Novo Nordisk Inc $18.32 10/15/2024 Food and Beverage Undisputed 01/23/2026 1096863781 CMS
Travere Therapeutics, Inc. $3.08 03/14/2024 Education Undisputed 01/23/2026 1149932676 CMS
Travere Therapeutics, Inc. $26.78 03/14/2024 Food and Beverage Undisputed 01/23/2026 1149932680 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.